## VRTX: Vertex Pharmaceuticals Incorporated - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.58 indicates fundamental undervaluation. Quality metrics strong (ROE 22%, ROA 12%). Caution: declining volume (55% of avg), momentum weakening (-1.6% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($435.41)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Vertex Pharmaceuticals (VRTX) Dips More Than Broader Market: What You Should Know**
- Source: www.sharewise.com | 20251231T120908 | Somewhat-Bullish | Relevance: 100%
- Vertex Pharmaceuticals (VRTX) closed down -1.31% in the latest trading session, underperforming the broader market despite a recent 8.03% appreciation over the past month. The company is anticipated to report strong earnings per share and revenue growth for its forthcoming report and the full year, with analysts closely monitoring estimate revisions. VRTX currently holds a Zacks Rank of #3 (Hold) and is valued at a premium compared to its industry, with a Forward P/E of 24.99.

**2. Generali Asset Management SPA SGR Acquires 6,942 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20260102T094821 | Somewhat-Bullish | Relevance: 100%
- Generali Asset Management SPA SGR has increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 41.8%, acquiring an additional 6,942 shares to now hold 23,569 shares valued at $9.23 million. This comes despite significant insider selling totaling $67.33 million during the quarter. Vertex Pharmaceuticals has outperformed earnings expectations and holds a consensus "Moderate Buy" rating with a target price of $502.05 from analysts.

**3. Coastline Trust Co Sells 3,145 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20260102T093821 | Neutral | Relevance: 100%
- Coastline Trust Co significantly reduced its stake in Vertex Pharmaceuticals (VRTX) by selling 3,145 shares in Q3, now owning 597 shares valued at $234,000. This comes alongside substantial insider selling in December, with executives selling shares worth millions. Despite these sales, analyst sentiment for VRTX remains largely positive, with a "Moderate Buy" consensus and an average price target of $502.

**4. VIRGINIA RETIREMENT SYSTEMS ET Al Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20260101T113708 | Somewhat-Bullish | Relevance: 100%
- Virginia Retirement Systems has made a new investment in Vertex Pharmaceuticals, purchasing 37,100 shares valued at approximately $14.53 million in the third quarter. This move aligns with increased institutional ownership of VRTX, which now stands at about 90.96% of the stock. Despite significant insider selling over the past three months, analysts maintain a "Moderate Buy" consensus for Vertex Pharmaceuticals, with a target price of $502.05, following a strong third-quarter earnings beat.

**5. Ethic Inc. Has $5.47 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251231T092127 | Somewhat-Bullish | Relevance: 99%
- Ethic Inc. increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 21.5% in the third quarter, bringing its holding to 13,971 shares valued at approximately $5.47 million. Despite institutional ownership reaching 90.96%, significant insider selling has occurred, with insiders offloading 151,073 shares worth $67.33 million in the past 90 days, reducing their total ownership to 0.20%. Vertex Pharmaceuticals exceeded Q3 earnings expectations with $4.80 EPS and revenue of $3.08 billion, prompting analysts to maintain a "Moderate Buy" rating with a consensus price target of $502.05.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-29 | Leerink Partner | $525 | $456 | +15% |
| 2025-12-10 | Wells Fargo | $515 | $460 | +12% |
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-29 | Leerink Partner | main | Outperform |
| 2025-12-10 | Wells Fargo | main | Overweight |
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 8 ($10.46M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-1.6% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $10M sold (8 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +14%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 22.3x stretched relative to 10% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (4 raises, avg +14%). Insider selling cluster ($10.5M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $115.9B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 22.3 |
| Current P/E | 24.5 |
| YoY Growth | 9.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.9% to 0.3% (-1.6% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.7pp (needs >4.0% for momentum thesis). MRS_5 (-0.3%) diverging from MRS_20 - short-term weakness emerging. Long-term uptrend intact (above SMA200 at 1.03x) but short-term weakness (below SMA20). MACD histogram bearish (-1.23), momentum weakening. RSI neutral at 54. Volume at 55% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 0.34% (CS: 44) | Neutral |
| RSI_14 | 53.5 | Neutral |
| MACD Histogram | -1.23 | Bearish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 1.034x | Above |
| vs SMA200 | 1.029x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $452.13
- **Stop Loss:** $435.41 (3.7% risk)
- **Target:** $485.57 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 86
- **Position Value:** $38,883.18
- **Portfolio %:** 38.88%
- **Risk Dollars:** $1,440.00
- **Risk Per Trade:** 1.44%
- **Modifiers:** L1 120% | L2 120% | Combined 1.44x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.20x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with stable risk appetite as 2026 trading begins. VIX at 14.51 (4th percentile) signals complacency while positive yield curve (+65bps) and moderate breadth (53.1%) support continuation. Focus on upcoming jobs data (Jan 9) and earnings season kickoff mid-January for directional catalysts.*

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-06 17:52 | MRS_20*